Private Market View

Nuclera

Cambridge, United Kingdom · Founded 2013 · Privately Held (backing)

PA Mark · $/share
$22
Sep 2026
Implied valuation
$154.5M
Total raised
$166.1M
Last round
Later Stage VC (Series C)
Jan 2026

Key facts

as of Sep 2026
  • Nuclera is valued at approximately $154.5M (~$22/share) as of Sep 2026, per Private Market View’s composite mark.
  • It has raised $166.1M across 9 recorded rounds; the latest was Later Stage VC (Series C) ($87.0M) in Jan 2026.
  • Notable investors include Innovate UK, Tech Nation Group, Puhua Capital, British Business Bank, Future Planet Capital — 22 tracked in total.
  • Status: Privately Held (backing).
PA Mark — composite indicative price
LOW confidence
~$22per share
implies $154.5M valuation · as of Sep 2026 · the exact daily mark is a member feature
Composed from 1 inputs:Round prints 100%
See the platform prints behind this mark →
Free account
See the evidence behind this price
  • ·Post-money valuations for all 9 rounds
  • ·The complete investor list — 22 names
  • ·Watchlist + deal alerts for Nuclera
Create free account
No card required

Recorded secondary trades

No prints on record

No secondary trades in Nuclera shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on Nuclera in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.

Funding rounds

9 rounds
Jan 2026Later Stage VC (Series C)$87.0M▮
Jun 2024Grant$1.4M▮
Mar 2024Accelerator/Incubator—▮
Jul 2022Later Stage VC (Series B)$67.1M▮
Oct 2019Later Stage VC (Series A)$11.2M▮
Full funding history →

Leadership

About Nuclera

Developer of a protein prototyping system designed to accelerate drug discovery workflows. The company's system helps construct design, expression, solubility characterization, and purification of target proteins in drug discovery programs and allows screening and synthesizing proteins on terms and bench, enabling healthcare professionals with integrated cell-free protein synthesis and digital microfluidics on smart cartridges.

Sector
Healthcare
HQ
Cambridge, United Kingdom
Founded
2013
Employees
134
Ownership
Privately Held (backing)